Endpoints in Gynaecological Oncology Clinical Trials
Gynaecological oncology clinical trials reveal that survival gains and trial design do not always align. Here is what clinical development teams should learn.
Nanocarriers Target the Eye for Better Ocular Drug Delivery
Ocular drug delivery faces major biological barriers. Nanocarriers could improve bioavailability, tissue targeting, controlled release, and treatment for difficult eye diseases.
Can Agentic AI Strengthen Clinical Safety Monitoring?
See how agentic AI could improve immune-related adverse event detection, safety data curation, and human review in oncology trials and across clinical safety monitoring.
Mitigation of PFAS Contamination in Pharma Manufacturing
PFAS contamination is a growing manufacturing risk. Explore the latest on the research, wastewater challenges, monitoring, remediation, and pharma implications.
Sustainable Drug Discovery Can Advance Global Health
Discover how medicinal chemistry can advance sustainable drug discovery, tackle neglected diseases, and improve access to medicines.
How Should Pharma Companies Audit AI Vendors?
“This is one of the riskiest industries there is because you're dealing with human lives, you're dealing with experimental protocols, and you're dealing with regulatory bodies where you might not get another shot at that clinical trial."